Alternative medicines and the liver

Liver International

Volumn 23, Issue 4, 2003, Pages 213-220

  Fogden, Edward ^a   Neuberger, James ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Animal, human; Complementary therapies ut (utilization); Drugs, Chinese herbals; Liver diseases; Phytotherapy; Plant extracts ae (adverse events); Plant extracts tu (therapeutic use); Safety

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALPHA INTERFERON; ASTRAGALUS MEMBRANACEUS EXTRACT; CHELIDONIUM EXTRACT; COMFREY EXTRACT; CROTALARIA EXTRACT; FLUOXETINE; GINGER EXTRACT; GLYCYRRHIZIC ACID; GOMISIN A; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; INTERFERON; IRINOTECAN; KAVA; LIV 52; NEOMINOPHAGEN C; PHYLLANTHUS AMARUS EXTRACT; PLANT EXTRACT; PYRROLIZIDINE ALKALOID; S ADENOSYLMETHIONINE; SALVIA MILTIORRHIZA EXTRACT; SILYMARIN; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISCUM ALBUM EXTRACT; VITAMIN K GROUP; XIAO CHAI HU TANG;

ACUTE HEPATITIS; ALCOHOL LIVER CIRRHOSIS; ALTERNATIVE MEDICINE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANXIETY DISORDER; ASCITES; ASTRAGALUS MEMBRANACEUS; BLEEDING; CHINESE HERB; CHINESE MEDICINE; CLINICAL RESEARCH; CROTALARIA; DEPRESSION; DISEASE EXACERBATION; DRUG METABOLISM; DRUG SAFETY; EDEMA; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; GLYCYRRHIZA; HEADACHE; HEPATITIS B; HEPATITIS C; HERBAL MEDICINE; HUMAN; HYPERICUM PERFORATUM; HYPERTENSION; HYPOKALEMIA; IMMUNOMODULATION; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MEDICAL PRACTICE; NAUSEA; PHYLLANTHUS; REVIEW; RISK ASSESSMENT; SALVIA MILTIORRHIZA; SIDE EFFECT; SILYBUM MARIANUM; SKIN MANIFESTATION; UNITED KINGDOM;

ANIMALS; COMPLEMENTARY THERAPIES; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; HUMANS; LIVER; LIVER DISEASES; PLANT EXTRACTS;

EID: 0142061465     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0676.2003.00843.x     Document Type: Review

References (65)

1. Zollman C, Vickers A. What is complementary medicine. BMJ 1999; 319: 693-6.
2. Ernst E. The role of complementary and alternative medicine. BMJ 2000; 321: 1133-5.
3. Strader D B, Bacon B R, Lindsay K L, La Breque D R, Morgan T, Wright E C, Allen J, Khokar M F, Hoofnagle J H, Seeff L B. Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol 2002; 97: 2391-7.
4. Delbanco T L. Bitter herbs: mainstream, magic and menace. Ann Intern. Med 1994; 121: 803-4.
5. Diamond J. Close encounters of an alternative kind. BMJ 2000; 321: 1163-4.
6. Cochrane Library: URL: www.update-software.com/Cochrane/default.htm
7. US Institute of Health National Centre for Complementary and Alternative Medicine URL: http://nccam.nih.gov
8. Shaw D, Leon C, Kiolev S, Murray V. Traditional remedies and food supplements. A 5-year toxicological study (1991-1995). Drug Safety 1997; 17: 342-6.
9. Mason S, Tovey P, Long A F. Evaluating complementary medicine: methodological challenges of randomised controlled trials. BMJ 2002; 325: 832-4.
10. Nahin R L, Straus S E. Research into complementary and alternative medicine: problems and potential. BMJ 2001; 322: 161-4.
11. Boigk G, Stroedter L, Herbst H, Waldschmidt J, Riecken E O. Schuppan D. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obstruction in rats. Hepatology 1987; 26: 643-9.
12. Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, Meryn S, Base W, Schneider B. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989; 9: 105-13.
13. Liu J, Manheimer E. Medicinal herbs for hepatitis C infection: a Cochrane hepatobiliary systematic review of randomized trials. Am J Gastroenterol 2003; 98: 538-44.
14. Buzzelli G, Moscarella S, Giusti A, Duchini A, Marena C, Lampertico M. A pilot study on the liver protective effect of silybinphospha-tidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol 1993; 31: 456-60.
15. Angulo P, Patel T, Jorgensen R A, Therneau T, Lindor K D. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000; 32: 897-900.
16. Lawrence V, Jacobs B, Dennehy C. Milk thistle: effects on liver disease and cirrhosis and clinical adverse effects. Evidence Report/Technology Assessment No. 21 (Contract 290-97-0012 to the San Antonio Evidence-based Practice Centre, based at the University of Texas Health Science Centre at San Antonio, and the Veterans Evidence-based Research, Dissemination, and Implementation Centre, a Veterans Affairs Services Research and Development Centre of Excellence), AHRQ Publication No. 01-E025, Agency for Healthcare Research and Quality, Rockville, MD, October 2000.
17. Jacobs B P, Dennehy C, Ramirez G, Sapp J, Lawrence V A. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am J Med 2002; 113: 506-15.
18. Bunout D, Hirsch S, Petermann M, de la Maza M P, Silva G, Kelly M, Ugarte G. Humaga H. Controlled study of the effect of silymarin on alcoholic liver disease. Rev Med Chile 1992; 120: 1370-5.
19. Trinchet J C, Coste T, Levy V G, Vivet F, Duchatekke V. Legendre C, Gotheil C, Beaugrand M I. A randomized double blind trial of silymarin in 116 patients with alcoholic hepatitis. Gastroenterol Clin Biol 1989; 13: 120-4.
20. Seeff L B, Lindsay K L. Bacon B. Kresina T F, Hoofnagle J H Complementary and alternative medicine in chronic liver disease. Hepatology 2001; 34(3): 595-603.
21. Arase Y, Ikeda K, Murashima N. The long-term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997; 79: 1491-500.
22. Van Rossum T G J. Vulto A G, Hop W C J, Brouwer J T, Niester H G. Schalm S W I. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double blind, randomized, placebo-controlled phase I/II trial. J. Gastroenterol Hepatol 1999; 14: 1093-9.
23. Schuppan D, Jia J, Brinkhaus B, Hahn E. Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology 1999; 30: 1099-104.
24. Hayashi J, Jajiyama W, Noguchi A. Nahashima K, Hirata M, Hayashi S, Kashiwagi S. Glycyrrhizin withdrawal followed by human lymphoblastoid interferon in the treatment of chronic hepatitis B. Gastroenterol Jpn 1991; 26: 742-6.
25. Liu J P, McIntosh H, Lin H. Chinese medicinal herbs for chronic hepatitis B (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software, 2003.
26. Liu J P, McIntosh H, Lin H. Chinese medicinal herbs for asymptomatic carriers of hepatitis B virus infection (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update Software, 2003.
27. Wang H J, Wang B E. Long term follow-up result of compound Dan Shen granule (861 Chong FuJi) in treating hepatofibrosis. Chin J Integr Trad West Med 1995; 5: 4-5.
28. Wang T L, Wang B E, Zhang H H, Liu J X, Duan Z P, Zhang J, Ma H. Li X M, Li N Z. Pathological study of the therapeutic effect on HBV-related liver fibrosis with herbal compound 861. Chin J Gastroenterol Hepatol 1998; 7: 148-53.
29. Shiota G, Maeta Y, Mukoyama T, Yanagidani A, Udagawa A, Oyama K, Yashima K, Kishimoto Y, Nakai Y, Miura T, Ito H, Murawaki Y, Kawasaki H. Effects of Sho-Saiko-to on hepatocarcinogenesis and 8-hydroxy-2′-deoxyguanosine formation. Hepatology 2002; 35: 1125-33.
30. Hardy M, Coulter I, Morton S C, Favreau J, Venuturupalli S, Chiappelli F, Rossi F, Orshansky G. Jungvig L K, Roth E A, Suttorp M J, Shekelle P S-Adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease. Evidence Report/Technology Assessment Number 64, AHRQ Publication No. 02-E034, Agency for Healthcare Research and Quality, Rockville, MD, October 2002.
31. Fleig W W, Morgan M Y, Hölzer M Aa European Multicenter Study Group The ayurvedic drug LIV. 52 in patients with alcoholic cirrhosis. Results of a prospective, randomized, double-blind, placebo-controlled clinical trial [Abstract]. J Hepatol 1997; 26(Suppl.1): 127.
32. Linde K, Mulrow C D. St. John's wort for depression (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford: Update Software, 2003.
33. Barnes J., Herbal medicinal products: an overview of regulation, quality, efficacy and safety. In: Neuberger J, ed. Horizons in Medicine 2003, No. 14. London: Royal College of Physicians of London, 2003.
34. Huang W F, Wen K C, Hsiao M L. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. J Clin Pharmacol 1997; 37: 344-50.
35. Ko R J. Adulterants in Asian Patent Medicines. N Engl J Med 1998; 339: 847.
36. Espinoza E O, Mann M -J, Bleasdell B. Arsenic and mercury in traditional Chinese herbal balls. N Engl J Med 1995; 333: 803-4.
37. Slifman N R, Obermeyer W R, Musser S M, Correll W A, Cichowicz S M, Love L A. Contamination of botanical dietary supplements by Digitalis lanata. N Engl J Med 1998; 339: 806-11.
38. Farrell G C. Drug-Induced Liver Disease. New York: Churchill Livingstone, 1994. ISBN 044304368X
39. Stricker B H C H. Drug-Induced Hepatic Injury, 2nd edn. Amsterdam: Elsevier, 1992. ISBN 0444813039
40. Risberg T, Vickers A, Bremnes R M, Wist E A, Kaasa S, Cassileth B R. Does use of alternative medicine predict survival from cancer. Eur J Cancer 2003; 39: 372-7.
41. Mathijssen R H J, Verweij J, de Bruijn P, Loos W J, Sparreboom A. Effects of St. John's Wort on Irinotecan Metabolism. J Natl Cancer Inst 2002; 94: 1247-9.
42. Crone C C, Wise T N. Survey of alternative medicine use among organ transplant patients. J. Transplant Coordination 1997; 7: 123-30.
43. Matthees B J, Anantachoti P, Kreitzer M J, Savik K, Hertz M I, Gross C R. Use of complementary therapies, adherence, and quality of life in lung transplant recipients. Heart Lung: J Acute Crit Care 2001; 30: 258-68.
44. Sheikh N M, Philen R M. Love L A. Chaparral-associated hepatotoxicity. Arch Int Med 1997; 157: 913-9.
45. Larrey D, Vial T. Pauwels A, Castot A, Biour M, David M, Michel H. Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med 1992; 117: 129-32.
46. Woolf G M, Petrovic L M, Rojter S E, Wainwright S, Villamil F G, Katkov W N, Michieletti P, Wanless I R, Stermitz F R, Beck J J, et al. Acute hepatitis associated with the Chinese herbal product Jin Bu Huan. Arch Int Med 1994; 121: 803-4.
47. Anderson I B, Mullen W H, Meeker J E, Khojasteh-Bakht S C, Oishi S, Nelson S, Blanc P. Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. Ann Intern Med 1996; 124: 726-34.
48. Parés A, Planas R, Torres M, Caballería J, Viver J M, Acero D, Panés J, Rigau J, Santos J, Rodés J. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 1998; 28: 615-21.
49. Van Rossum T G J, Vulto A G, Hop W C J, Schalm S W. Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 2432-7.
50. Prince M, Mitchison H C, Ashley D, Burke D A, Edwards N. Bramble M G, James O F, Jones D E. Oral anti-oxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multi-centre, randomised placebo-controlled cross-over trial. Aliment Pharmacol Ther 2003; 17: 137-43.
51. Hirayama C, Okumura M, Tanikawa K, Yano M, Mizuta M, Ogawa N. A multicenter randomized clinical trial of Shosaiko-to in chronic hepatitis. Gastroenterol Jpn 1989; 24: 715-9.
52. Oka H, Yamamoto S, Kuroki T, Harihara S, Marumo T. Kim S R, Monna T, Kobayashi K, Tango T. Prospective study of chemoprevention of hepatocellular carcinoma with sho-saiko-to (TJ-9). Cancer 1995; 76: 743-9.
53. Batey R G, Bensousson A, Fan Y Y, Bollipo S, Hossain M. Preliminary report of a randomized, double-blind placebo-controlled trial of a Chinese herbal medicine preparation CH100 in the treatment of chronic hepatitis C. J Gastroenterol Hepatol 1998; 13: 244-7.
54. DeSilva H A, Saparamadu P A, Thabrew M I, Pathmeswaran A, Fonseka M M D, de Silva H J. LIV. 52 in alcoholic liver disease: a prospective, controlled trial. J Ethnopharmacol 2003; 84: 47-50.
55. Miller G M. Herbal medicinals. Arch Intern Med 1998; 158(9): 2200-11.
56. Winslow L C, Kroll D J. Herbs as medicines. Arch Intern Med 1998; 158: 2192-9.
57. Anonymous. Why bother about cytochrome P450 enzymes. Drugs Ther Bull 2000; 38: 93-5.
58. Ezzo J, Berman B M, Vickers A J, Linde K. Investigating alternative medicine therapies in randomized controlled trials. J Am Med Assoc 1998; 280: 1626-30.
59. Campion E. Why unconventional medicine? N Engl J Med 1993; 328: 282-3.
60. Studdert D M, Eisenberg D M, Miller F H, Curto D A, Kaptchuk T A. Medical malpractice implications of alternative medicine. J Am Med Assoc 1998; 280: 1610-5.
61. Feder G, Katz T. Randomised controlled trials for homeopathy Who wants to know the results? 2002; 324: 498-9.
62. Rees L, Weil A. Integrated medicine. BMJ 2001; 322: 119-20.
63. Vickers A. Recent advances: complementary medicine. BMJ 2000; 321: 683-6.
64. Mills S Y. Regulation in complementary and alternative medicine. BMJ 2001; 322: 158-60.
65. Vickers A, Zollman. Herbal medicine. BMJ 1999; 319: 1050-3.